Drug Distributors And Major Pharmaceutical Company Reach $26 Billion Global Settlement With States To End Opioid Litigation

Cozen O'Connor
Contact

Cozen O'Connor

  • A bipartisan group of AGs reached a $26 billion global settlement with three major drug distributors and Johnson & Johnson (“J&J”) (collectively “Companies”), pending approval by the vast majority of states and municipalities, to release the Companies from all civil liability relating to the opioid crisis.
  • Under the terms of the agreement, negotiated by a team of lawyers that included Cozen O’Connor’s JB Kelly, the three distributors collectively will pay up to $21 billion over 18 years and J&J will pay up to $5 billion over nine years, with the substantial majority of the funds to be spent on opioid treatment and prevention. In addition, the distributors will establish an independent clearinghouse to provide aggregated data and analytics about drug distribution nationwide and will use data-driven systems to detect suspicious opioid orders from customer pharmacies. J&J agreed to stop selling and promoting opioids, and to share clinical trial data under the Yale University Open Data Access Project.
  • States and municipalities have 30 days to review the deal and provide formal approval.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Cozen O'Connor | Attorney Advertising

Written by:

Cozen O'Connor
Contact
more
less

Cozen O'Connor on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.